LEPR

Biomarker

LEPR encodes the leptin receptor and is involved in energy balance regulation. Pathogenic variants are relevant in rare obesity disorders and therapeutic eligibility.

Approvals
1
Indications
1
Therapies
1
Mapped tests
1

Where this biomarker is used

Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.

Indication-specific approvals

Approvals where LEPR is defined directly in the indication labeling.

IndicationBiomarker criteriaTherapies
Obesity
Other · Metabolic
  • Variants (Pathogenic/Likely Pathogenic) and Variants of Uncertain Significance
Tumor-agnostic approvals

Approvals defined at the solid tumor level where LEPR is part of the eligibility criteria.

No tumor-agnostic approvals are currently mapped for this biomarker.

Tests that measure this biomarker

These assays report LEPR as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.

Test
POMC/PCSK1/LEPR CDx Panel
Prevention Genetics
Method
NGS
Specimen
Whole blood

Reports LEPR as part of its biomarker panel.

This view is scoped to LEPR. You can also see how it compares with other biomarkers and indications on the Know Your Companions™ map.